23andMe Holding Co. (NASDAQ:ME - Get Free Report)'s stock price traded up 13.1% on Friday . The stock traded as high as $3.63 and last traded at $3.55. 332,099 shares traded hands during mid-day trading, an increase of 18% from the average session volume of 281,945 shares. The stock had previously closed at $3.14.
Analyst Upgrades and Downgrades
Separately, TD Cowen lowered shares of 23andMe from a "strong-buy" rating to a "strong sell" rating in a research note on Wednesday, August 7th.
Read Our Latest Report on 23andMe
23andMe Stock Up 13.1 %
The firm has a market cap of $92.73 million, a P/E ratio of -0.14 and a beta of 1.26. The firm has a fifty day moving average of $4.96 and a 200-day moving average of $7.12.
23andMe (NASDAQ:ME - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share (EPS) for the quarter. 23andMe had a negative return on equity of 129.98% and a negative net margin of 318.39%. The company had revenue of $44.07 million for the quarter, compared to the consensus estimate of $50.30 million.
Institutional Trading of 23andMe
Several institutional investors and hedge funds have recently bought and sold shares of the business. Levin Capital Strategies L.P. acquired a new position in shares of 23andMe in the second quarter valued at approximately $61,000. Vanguard Personalized Indexing Management LLC grew its position in shares of 23andMe by 410.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company's stock valued at $35,000 after purchasing an additional 71,204 shares during the last quarter. Point72 DIFC Ltd acquired a new position in shares of 23andMe in the second quarter valued at approximately $43,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of 23andMe in the second quarter valued at approximately $203,000. Finally, AQR Capital Management LLC grew its position in shares of 23andMe by 145.8% in the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company's stock valued at $174,000 after purchasing an additional 263,468 shares during the last quarter. Institutional investors own 36.10% of the company's stock.
23andMe Company Profile
(
Get Free Report)
23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.
Further Reading
Before you consider 23andMe, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 23andMe wasn't on the list.
While 23andMe currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
